| BIOGEN INC. DL -,0005 | 260.900 / 0.00% |
| Date/Time | 11/22 / 08:00 |
| Chg. / Chg.(%) | 0.000 / 0.00% |
| Bid | 259.600 / 19 |
| Ask | 262.100 / 19 |
| Open | 260.900 |
| Previous Close | 260.900 |
| High | 260.900 |
| Low | 260.900 |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | 1 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | gettex |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| München | 258.65 |  |
0 |
| Lang & Schwa.. | 259.250 | |
|
| gettex | 260.900 | |
|
| Stuttgart | 258.550 | |
|
| NASDAQ | 288.4600 |  |
1,292,420 |
| Cboe US | 288.62 | |
92,192 |
| IEX | 288.51 | |
39,017 |
| London Inter.. | 287.50 | 815 | |
| TradeGate | 261.000 | 514 | |
| Frankfurt | 257.1500 | 210 | |
| Xetra | 260.20 | |
126 |
| Vienna Globa.. | 259.75 | |
94 |
| Hamburg | 256.35 | 0 | |
| Düsseldorf | 255.95 | 0 | |
| Berlin | 261.05 | 0 | |
| Hannover | 256.35 | 0 | |
| SIX Swiss Ex.. | 232.00 | |
|
| Mexico | 5,600.00 | 113 |
News
- Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
11/21/2019 / 13:30 - GlobeNewswire - AZTherapies Announces Appointment of Ernest D. Penachio as Vice President of Manufacturing Operations and CMC
11/06/2019 / 22:05 - GlobeNewswire - Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
11/06/2019 / 13:30 - GlobeNewswire - Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
11/04/2019 / 22:30 - GlobeNewswire - Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
10/30/2019 / 12:30 - GlobeNewswire
Personal area
Real-timeClick on 
to activate push quotes.
to activate push quotes.